Yeji daily digest
Thu, Jul 9, 2026 — Thu, Jul 23, 2026
1 catalyst ahead
Upcoming catalysts · next 14 days
### Sat, Jul 11, 2026
- $CORT — relacorilant (hypertension secondary to hypercortisolism) · PDUFA
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
Yeji surfaces biotech catalysts from SEC filings, ClinicalTrials.gov, and the FDA. Not investment advice — see disclaimer.